Form 4: HeartBeam Director Jaff Granted 20,689 RSUs

HeartBeam, Inc. Director Michael R. Jaff was granted 20,689 Restricted Stock Units, vesting in two tranches by mid-2026.

Summary

• Michael R. Jaff, a Director of HeartBeam, Inc. (BEAT), reported the acquisition of 20,689 shares of common stock.
• These shares were granted as Restricted Stock Units (RSUs) on February 9, 2026, with a transaction price of $0.
• The RSUs will vest in two equal tranches: one half on March 31, 2026, and the remaining half on June 30, 2026.
• The vesting commencement date for these RSUs was January 1, 2026.
• The RSUs were issued under the Company's 2022 Equity Incentive Plan.
• Following this transaction, Mr. Jaff beneficially owns 95,809 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard corporate governance practices and aligning director incentives with shareholder interests, without indicating any significant operational or financial shifts.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with long-term shareholder value through equity ownership.
• Issuance from the 2022 Equity Incentive Plan indicates a structured approach to executive and director compensation.

Negatives

• The transaction itself does not present immediate negatives, as it is a standard equity compensation event.

Risks

• No specific risks were mentioned in this Form 4 filing, which primarily reports an equity compensation grant.

Future Outlook

The filing indicates future vesting events for the granted RSUs on March 31, 2026, and June 30, 2026, aligning director compensation with future company performance.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Stock Units, is a common practice in the medical technology and biotechnology sectors to attract and retain key talent, including directors. This aligns with industry standards for incentivizing long-term commitment and performance.

Comparison to Industry Standards

• The grant of RSUs to a director is a standard practice in the U.S. public company landscape, particularly in growth-oriented sectors like medical devices, to align executive and director incentives with shareholder value creation.
• Companies such as Medtronic (MDT) and Abbott Laboratories (ABT) frequently utilize RSU grants as a component of their non-employee director compensation packages, often with multi-year vesting schedules to encourage sustained engagement and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with long-term shareholder value, potentially fostering more strategic decision-making aimed at increasing stock price.
• Employees: No direct impact on employees is indicated by this specific filing, though the existence of an equity incentive plan suggests broader employee compensation strategies.

Next Steps

• First half of the Special RSU (10,344.5 shares) will vest on March 31, 2026.
• Remaining half of the Special RSU (10,344.5 shares) will vest on June 30, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director, which is a standard corporate governance practice. It does not contain information that would fundamentally alter the investment thesis for HeartBeam, Inc. While it aligns director incentives, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider broader company performance and market conditions.

Keywords

HeartBeam, BEAT, Form 4, SEC filing, Restricted Stock Units, RSU grant, Director compensation, equity incentive plan, insider transaction, beneficial ownership